

09-J1000-11

Original Effective Date: 08/15/09

Reviewed: 11/12/25

Revised: 06/01/26

Subject: Golimumab (Simponi[®], Simponi[®] Aria) Injection and Infusion

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Dosage/ Administration	Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions
Related Guidelines	Other	References	Updates		

DESCRIPTION:

Golimumab (Simponi, Simponi Aria) is one of five commercially available tumor necrosis factor (TNF)-alpha inhibitors, not counting biosimilars as separate products, available in the United States. Tumor necrosis factor, a proinflammatory cytokine, initiates the body's defense response to local injury by stimulating the production of inflammatory mediators and signaling immune cells. TNF may augment host defense mechanisms when in low concentration, but large amounts of TNF can lead to excessive inflammation and tissue deterioration. In rheumatoid arthritis, activated T-cells migrate into the synovial lining of the joint where TNF is released and joint destruction begins. The intestinal mucosa from patients with Crohn's disease or [ulcerative colitis](#) has been associated with high levels of TNF as compared to healthy individuals; a similar elevation in TNF has been demonstrated in patients with psoriasis.

Golimumab was approved by the US Food and Drug Administration (FDA) for the treatment of moderately to severely active [rheumatoid arthritis](#) (RA) in combination with methotrexate, active [psoriatic arthritis](#) (PsA) as monotherapy or in combination with methotrexate, and active [ankylosing spondylitis](#) (AS) in 2009. In May 2013, the approval was expanded to include treatment of ulcerative colitis (UC) in persons 18 years of age and older refractory to conventional therapy. An intravenous (IV) formulation of golimumab (Simponi Aria) indicated for the treatment of adults with moderate or severe rheumatoid arthritis in combination with methotrexate was FDA-approved in July 2013. In October 2017, the indications for Simponi Aria were expanded to include the treatment of adults with active PsA and active AS. In September 2020, the indications were again expanded to include the treatment of active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older, and the age group for active PsA was expanded to include children 2 years of age and older. In October 2025, the indication for moderately to severely active UC was expanded to include pediatric patients weighing at least 15 kg. The TNF-alpha inhibitors as a class are considered to have similar efficacy and safety for the majority of indications. Golimumab also has an orphan designation for the treatment of pediatric ulcerative colitis (2012). Golimumab is administered as a subcutaneous injection every 4 weeks, which is similar to certolizumab pegol (Cimzia) but less frequently than the indicated dosing frequency of the other two FDA-approved subcutaneously administered TNF-alpha inhibitors, adalimumab (Humira) and etanercept (Enbrel). The IV formulation is administered every 8 weeks. The National Comprehensive Cancer Network (NCCN) guidelines on the Management of Immune Checkpoint Inhibitor-Related-Toxicities now

include all TNF alpha inhibitors as options to be considered for the management of moderate or severe immunotherapy-related inflammatory arthritis if unable to taper corticosteroids after 1 week.

RHEUMATOID DISORDERS

Ankylosing spondylitis (AS)

Ankylosing spondylitis (AS) is a form of chronic inflammatory arthritis characterized by sacroiliitis, enthesitis, and a marked propensity for sacroiliac joint and spinal fusion. AS is distinguished by universal involvement with sacroiliac joint inflammation or fusion and more prevalent spinal ankylosis. Goals of treatment for AS are to reduce symptoms, maintain spinal flexibility and normal posture, reduce functional limitations, maintain work ability, and decrease disease complications. The mainstays of treatment have been nonsteroidal anti-inflammatory drugs (NSAIDs) and exercise/physical therapy.

NSAIDs are used as first line therapy for patients with active AS, with continuous treatment with NSAIDs being preferred. In patients with stable disease, NSAIDs may be used on-demand to decrease the risk of adverse effects with long term use. No particular NSAID is recommended as a preferred option. Biologics should be used in patients who continue to have persistently high disease activity despite NSAIDs. Failure of standard treatment with NSAIDs can be defined as a lack of response (or intolerance) to at least 2 NSAIDs after at least a 4-week duration of therapy in total.

Tumor necrosis factor (TNF) inhibitors or interleukin (IL)-17 inhibitors are recommended as initial biologic therapy. Other present comorbidities (e.g., inflammatory bowel disease, psoriasis, uveitis) can help guide selection of the initial biologic agent/drug class. Patients who have an inadequate response to a TNF inhibitor or IL-17 inhibitor may switch to a biologic of the other drug class, or switch to a Janus kinase (JAK) inhibitor. Patients with secondary failure to a biologic (presence of antidrug antibodies) may switch to another biologic of the same or different mode of action.

Systemic glucocorticoids should generally not be used in the treatment of AS. Short-term glucocorticoid injections may be used in select patients with peripheral signs and symptoms. Conventional disease-modifying antirheumatic drugs (cDMARDs) (e.g., methotrexate, sulfasalazine, leflunomide) are not recommended as treatment due to their lack of efficacy. However, sulfasalazine may be considered in patients with peripheral arthritis.

Polyarticular Juvenile Idiopathic Arthritis (PJIA)

Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis (PS), most commonly presenting with peripheral arthritis, dactylitis, enthesitis, and spondylitis. Active PsA is defined as symptoms at an unacceptably bothersome level as reported by the patient due to one of the following: actively inflamed joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and/or extraarticular manifestations such as uveitis or inflammatory bowel disease (IBD). Disease severity is based on the assessment of the level of disease activity at a given point in time, and the presence/absence of poor prognostic factors and long-term damage. Severe PsA is defined in the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) guidelines for PsA and includes the presence of one or more of the following:

- Erosive disease
- Elevated markers of inflammation (e.g., erythrocyte sedimentation rate [ESR], C-reactive protein [CRP]) attributable to PsA
- Long-term damage that interferes with function (e.g., joint deformities, vision loss)
- Highly active disease that causes a major impairment in quality of life, such as:
 - Active PsA at many sites including dactylitis and enthesitis
 - Function-limiting PsA at a few sites
- Rapidly progressive disease

Treatment involves the use of a variety of interventions, including many agents used for the treatment of other inflammatory arthritis disorders, particularly spondyloarthritis and rheumatoid arthritis, and other management strategies of the cutaneous manifestations of psoriasis. Symptomatic treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and local glucocorticoid injections. Only patients with very mild peripheral disease may sufficiently benefit from NSAIDs as monotherapy, and instead patients are typically treated with disease-modifying antirheumatic drugs (DMARDs) and/or biologics. Efficacy of DMARD and biologic therapies should be assessed 3 months after initiation, and if adequate improvement is not seen then the treatment regimen should be updated or changed. The ACR-NPF guidelines for PsA recommend a treat-to-target approach in therapy, regardless of disease activity, and treatment recommendations for active disease are as follows:

- Treatment naïve patients:
 - First line options include oral small molecules (OSM), tumor necrosis factor (TNF) inhibitors, interleukin (IL)-17 inhibitors, and IL-12/23 inhibitors
 - OSM (i.e., methotrexate [MTX], sulfasalazine, cyclosporine, leflunomide, apremilast) should be considered if the patient does not have severe PsA, does not have severe PS, prefers oral therapy, has concern over starting a biologic, or has contraindications to TNF inhibitors
 - Biologics (e.g., TNF inhibitor, IL-17 inhibitor, IL-12/23 inhibitor) are recommended as a first line option in patients with severe PsA and/or severe PS
- Previous treatment with OSM and continued active disease:
 - Switch to a biologic (i.e., TNF inhibitor, IL-17 inhibitor, IL-12/23 inhibitor); recommended over switching to a different OSM
 - Biologic monotherapy is conditionally recommended over biologic plus MTX combination therapy
 - Switch to a different OSM (except apremilast) OR add on apremilast to current OSM therapy; recommended over adding another OSM
 - Add another OSM (except apremilast) to current OSM therapy; may consider for patients that have exhibited partial response to current OSM
 - Switch to apremilast monotherapy; may be considered instead of adding apremilast to current OSM therapy if the patient has intolerable side effects with the current OSM
- Previous treatment with a biologic and continued active disease:
 - Switch to another biologic (e.g., TNF inhibitor, IL-17 inhibitor, IL-12/23 inhibitor, abatacept, or tofacitinib) as monotherapy
 - Add MTX to the current biologic; may consider adding MTX in patients with a partial response to current biologic therapy

The European Alliance of Associations for Rheumatology (EULAR) guidelines for PsA (2023 update) also recommend a treat-to-target approach in therapy. MTX (preferred) or another conventional synthetic disease-modifying antirheumatic drug (csDMARD) (e.g., sulfasalazine, leflunomide) should be used for initial therapy. If the treatment target is not achieved with a csDMARD, a biologic should be initiated with preference of product being based on patient specific disease characteristics. Biologics include TNF inhibitors, IL-12/23 inhibitors, IL-17A inhibitors, IL-17A/F inhibitors, IL-23 inhibitors, and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) analogs. No order of preference of biologics is provided since none have demonstrated superiority for joint involvement, however, CTLA4 analogs are least preferred due to limited efficacy in clinical trials. The use of a Janus kinase (JAK) inhibitor (e.g., tofacitinib, upadacitinib) may be used after failure of a biologic or if biologics are not clinically appropriate for the patient. However, careful consideration should be applied prior to using a JAK inhibitor due to the increased risk of cardiovascular and malignancy events in older patients with RA and cardiovascular risk factors. A phosphodiesterase-4 (PDE4) inhibitor (i.e., apremilast) may be considered in patients with mild disease and an inadequate response to at least one csDMARD, in whom neither a biologic nor a JAK

inhibitor is appropriate. Patients with an inadequate response to a biologic or JAK inhibitor may switch to a different drug within the same class or switch to a different mode of action. Adding MTX to a biologic may increase drug survival by limiting the development of antidrug antibodies, especially for TNF inhibitors.

Psoriatic Arthritis (PsA)

Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis (PS), most commonly presenting with peripheral arthritis, dactylitis, enthesitis, and spondylitis. Active PsA is defined as symptoms at an unacceptably bothersome level as reported by the patient due to one of the following: actively inflamed joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and/or extraarticular manifestations such as uveitis or inflammatory bowel disease (IBD). Disease severity is based on the assessment of the level of disease activity at a given point in time, and the presence/absence of poor prognostic factors and long-term damage. Severe PsA is defined in the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) guidelines for PsA and includes the presence of one or more of the following:

- Erosive disease
- Elevated markers of inflammation (e.g., erythrocyte sedimentation rate [ESR], C-reactive protein [CRP]) attributable to PsA
- Long-term damage that interferes with function (e.g., joint deformities, vision loss)
- Highly active disease that causes a major impairment in quality of life, such as:
 - Active PsA at many sites including dactylitis and enthesitis
 - Function-limiting PsA at a few sites
- Rapidly progressive disease

Treatment involves the use of a variety of interventions, including many agents used for the treatment of other inflammatory arthritis disorders, particularly spondyloarthritis and rheumatoid arthritis, and other management strategies of the cutaneous manifestations of psoriasis. Symptomatic treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and local glucocorticoid injections. Only patients with very mild peripheral disease may sufficiently benefit from NSAIDs as monotherapy, and instead patients are typically treated with disease-modifying antirheumatic drugs (DMARDs) and/or biologics. Efficacy of DMARD and biologic therapies should be assessed 3 months after initiation, and if adequate improvement is not seen then the treatment regimen should be updated or changed. The ACR-NPF guidelines for PsA recommend a treat-to-target approach in therapy, regardless of disease activity, and treatment recommendations for active disease are as follows:

- Treatment naïve patients:
 - First line options include oral small molecules (OSM), tumor necrosis factor (TNF) inhibitors, interleukin (IL)-17 inhibitors, and IL-12/23 inhibitors
 - OSM (i.e., methotrexate [MTX], sulfasalazine, cyclosporine, leflunomide, apremilast) should be considered if the patient does not have severe PsA, does not have severe PS, prefers oral therapy, has concern over starting a biologic, or has contraindications to TNF inhibitors
 - Biologics (e.g., TNF inhibitor, IL-17 inhibitor, IL-12/23 inhibitor) are recommended as a first line option in patients with severe PsA and/or severe PS
- Previous treatment with OSM and continued active disease:
 - Switch to a biologic (i.e., TNF inhibitor, IL-17 inhibitor, IL-12/23 inhibitor); recommended over switching to a different OSM
 - Biologic monotherapy is conditionally recommended over biologic plus MTX combination therapy

- Switch to a different OSM (except apremilast) OR add on apremilast to current OSM therapy; recommended over adding another OSM
- Add another OSM (except apremilast) to current OSM therapy; may consider for patients that have exhibited partial response to current OSM
- Switch to apremilast monotherapy; may be considered instead of adding apremilast to current OSM therapy if the patient has intolerable side effects with the current OSM
- Previous treatment with a biologic and continued active disease:
 - Switch to another biologic (e.g., TNF inhibitor, IL-17 inhibitor, IL-12/23 inhibitor, abatacept, or tofacitinib) as monotherapy
 - Add MTX to the current biologic; may consider adding MTX in patients with a partial response to current biologic therapy

The European Alliance of Associations for Rheumatology (EULAR) guidelines for PsA (2023 update) also recommend a treat-to-target approach in therapy. MTX (preferred) or another conventional synthetic disease-modifying antirheumatic drug (csDMARD) (e.g., sulfasalazine, leflunomide) should be used for initial therapy. If the treatment target is not achieved with a csDMARD, a biologic should be initiated with preference of product being based on patient specific disease characteristics. Biologics include TNF inhibitors, IL-12/23 inhibitors, IL-17A inhibitors, IL-17A/F inhibitors, IL-23 inhibitors, and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) analogs. No order of preference of biologics is provided since none have demonstrated superiority for joint involvement, however, CTLA4 analogs are least preferred due to limited efficacy in clinical trials. The use of a Janus kinase (JAK) inhibitor (e.g., tofacitinib, upadacitinib) may be used after failure of a biologic or if biologics are not clinically appropriate for the patient. However, careful consideration should be applied prior to using a JAK inhibitor due to the increased risk of cardiovascular and malignancy events in older patients with RA and cardiovascular risk factors. A phosphodiesterase-4 (PDE4) inhibitor (i.e., apremilast) may be considered in patients with mild disease and an inadequate response to at least one csDMARD, in whom neither a biologic nor a JAK inhibitor is appropriate. Patients with an inadequate response to a biologic or JAK inhibitor may switch to a different drug within the same class or switch to a different mode of action. Adding MTX to a biologic may increase drug survival by limiting the development of antidrug antibodies, especially for TNF inhibitors.

INFLAMMATORY BOWEL DISEASE

Ulcerative Colitis (UC)

Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting the large intestine. It typically starts with inflammation of the rectum, but often extends proximally to involve additional areas of the colon. The most common symptom is bloody diarrhea, but urgency, tenesmus, abdominal pain, malaise, weight loss, and fever can also be associated. UC commonly has a gradual onset and will present with periods of spontaneous remission and subsequent relapses.

Disease severity is based on patient-reported outcomes (e.g., bleeding, bowel habits, bowel urgency), inflammatory burden (e.g., endoscopic assessment, inflammatory markers), disease course, and disease impact. Commonly assessed symptoms include frequency and timing of bowel movements, rectal bleeding, bowel urgency, abdominal pain, bowel cramping, and weight loss. Poor prognostic factors include less than 40 years of age at diagnosis, extensive colitis, severe endoscopic disease, hospitalization for colitis, elevated C-reactive protein (CRP), and low serum albumin. Therapeutic management in UC should be guided by the extent of bowel involvement, assessment of disease activity (i.e., quiescent, mild, moderate, or severe), and disease prognosis. Treatment response should be evaluated 12 weeks after initiation of therapy to confirm efficacy and safety.

The American College of Gastroenterology (ACG) published recommendations and guidance (2025) for the management of moderate-to-severe UC:

General treatment information:

- Patients with mildly to moderately active UC and a number of prognostic factors associated with an increased risk of hospitalization or surgery should be treated with therapies for moderate-to-severe disease
- Patients with mildly to moderately active UC who are not responsive (or are intolerant) to 5-aminosalicylate (5-ASA) therapies (e.g., balsalazide, mesalamine, sulfasalazine) should be treated as patients with moderate-to-severe disease

Corticosteroid therapy:

- In patients with moderately active UC, recommend oral budesonide multi-matrix system (MMX) for induction of remission
 - In patients with moderately active UC, consider nonsystemic corticosteroids such as budesonide MMX before the use of systemic therapy
- Recommend oral systemic corticosteroids to induce remission in UC of any extent
 - In patients with severely active UC, consider systemic corticosteroids rather than topical corticosteroids
- Recommend against systemic, budesonide MMX, or topical corticosteroids for maintenance of remission

Disease modifying antirheumatic drug (DMARD) therapy:

- Recommend against monotherapy with thiopurines or methotrexate for induction of remission
- 5-ASA therapy could be used as monotherapy for induction of moderately but not severely active UC
- 5-ASA therapy for maintenance of remission is likely not as effective in prior severely active UC as compared with prior moderately active UC
- Suggest thiopurines for maintenance of remission in patients now in remission due to corticosteroid induction
- Suggest against using methotrexate for maintenance of remission

Biologic/advanced therapy:

- Recommend the following drugs for induction of remission and continuing the same drug for maintenance of remission:
 - Anti-tumor necrosis factor (TNF) agents (e.g., infliximab, adalimumab, golimumab), ustekinumab, guselkumab, mirikizumab, risankizumab, vedolizumab, tofacitinib, upadacitinib, sphingosine-1-phosphate (S1P) receptor modulators (e.g., ozanimod, etrasimod)
 - Most clinical trials and available data demonstrate a benefit of using the steroid-sparing therapy that induces remission to maintain that remission
- When infliximab is used as induction therapy, recommend combination therapy with a thiopurine
 - Data on combination anti-TNF and immunomodulators in moderately to severely active UC only exist for infliximab and thiopurines
- Infliximab is the preferred anti-TNF therapy for patients with moderately to severely active UC
- Recommend vedolizumab as compared to adalimumab for induction and maintenance of remission
- Patients who are primary nonresponders to an anti-TNF (defined as lack of therapeutic benefit after induction and despite sufficient serum drug concentrations) should be evaluated and considered for alternative mechanisms of disease control (e.g., in a different class of therapy) rather than cycling to another drug within the anti-TNF class

- Biosimilars to anti-TNF therapies and to ustekinumab are acceptable substitutes for originator therapies. Delays in switching should not occur and patients and clinicians should be notified about such changes

The American Gastroenterology Association (AGA) published recommendations and guidance (2018) for the management of mild-to-moderate UC:

- In patients with moderate disease activity, suggest using high dose mesalamine (greater than 3 g/day) with rectal mesalamine for induction of remission and maintenance of remission
- Add either oral prednisone or budesonide MMX in patients that are refractory to optimized oral and rectal 5-ASA, regardless of disease extent
- If progression to moderate-to-severe disease activity occurs, or if the patient is at high risk for colectomy despite therapy, consider escalating to treatment for moderate-to-severe disease with immunomodulators and/or biologics

The American Gastroenterology Association (AGA) published recommendations and guidance (2024) for the management of moderate-to-severe UC:

General treatment information:

- Suggest early use of advanced therapy (e.g., biologics, ozanimod, etrasimod), with or without immunomodulator therapy (e.g., thiopurines), rather than treatment with 5-ASA and a gradual step up to biologic/immunomodulator therapy after 5-ASA treatment failure (conditional recommendation, very low certainty of evidence)
 - Patients with less severe disease or those who place a higher value on the safety of 5-ASA therapy over the efficacy of immunosuppressives may reasonably choose gradual step therapy with 5-ASA therapy

DMARD therapy:

- Suggest against using thiopurine monotherapy for inducing remission
- Suggest thiopurine monotherapy may be used for maintaining remission typically induced with corticosteroids
- Suggest against using methotrexate monotherapy for inducing or maintaining remission

Advanced therapy:

- Recommend using one of the following advanced therapies over no treatment:
 - Infliximab, golimumab, vedolizumab, tofacitinib, upadacitinib, ustekinumab, ozanimod, etrasimod, risankizumab, guselkumab
- Suggest using one of the following advanced therapies over no treatment:
 - Adalimumab, filgotinib*, mirikizumab (*not currently approved by the Food and Drug Administration)
- Biosimilars of infliximab, adalimumab, and ustekinumab can be considered equivalent to their originator drug in their efficacy
- Suggest the use of infliximab in combination with an immunomodulator over infliximab or an immunomodulator alone
- Suggest the use of adalimumab or golimumab in combination with an immunomodulator over adalimumab, golimumab or immunomodulator monotherapy

Advanced therapy-naïve patients (first-line therapy):

- Suggest that a higher or intermediate efficacy medication be used rather than a lower efficacy medication

- Higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab
- Intermediate efficacy: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab
- Lower efficacy: adalimumab

Prior exposure to one or more advanced therapies, particularly TNF antagonists:

- Suggest that a higher or intermediate efficacy medication be used rather than a lower efficacy medication
 - Higher efficacy: tofacitinib, upadacitinib, ustekinumab
 - Intermediate efficacy: filgotinib, mirikizumab, risankizumab, guselkumab
 - Lower efficacy: adalimumab, vedolizumab, ozanimod, etrasimod

POSITION STATEMENT:

Drug Waste Reduction: Additional medical necessity criteria for dose optimization may apply to intravenous Simponi Aria depending on the requested dose and member's benefit. Refer to Medical Coverage Guideline [Drug Waste Reduction, 09-J5000-54](#).

Site of Care: If intravenous golimumab (Simponi Aria) is administered in a hospital-affiliated outpatient setting, additional requirements may apply depending on the member's benefit. Refer to [09-J3000-46: Site of Care Policy for Select Specialty Medications](#).

Comparative Effectiveness [Simponi ONLY (does NOT include Simponi Aria)]

The Food and Drug Administration has deemed the drug(s) or biological product(s) in this coverage policy to be appropriate for self-administration or administration by a caregiver (i.e., not a healthcare professional). Therefore, coverage (i.e., administration) in a provider-administered setting such as an outpatient hospital, ambulatory surgical suite, or emergency facility is not considered medically necessary.

NOTE: The list of self-administered products with prerequisites for certain indications can be found at [Preferred Agents and Drug List](#).

SUBCUTANEOUS SIMPONI (PHARMACY BENEFIT)

Initiation of subcutaneous golimumab (Simponi) **meets the definition of medical necessity** when **ALL** of the following are met ("1" to "6"):

1. **ONE** of the following ("a", "b", or "c"):
 - a. The member has been treated with subcutaneous golimumab (starting on samples is not approvable) within the past 90 days
 - b. The prescriber states the member has been treated with subcutaneous golimumab (starting on samples is not approvable) within the past 90 days **AND** is at risk if therapy is changed
 - c. **BOTH** of the following ("i" and "ii"):
 - i. Subcutaneous golimumab will be used for the treatment of an indication listed in Table 1, and **ALL** of the indication-specific criteria are met
 - ii. **EITHER** of the following if the member has an FDA-approved indication ("I" or "II")
 - I. The member's age is within FDA labeling for the requested indication for subcutaneous golimumab

- II. The prescriber has provided information in support of using subcutaneous golimumab for the member's age for the requested indication
2. If requested for a diagnosis of ulcerative colitis (UC), the member weighs 15 kg (33 lbs) or greater
 3. The prescriber is a specialist in the area of the member's diagnosis (e.g., rheumatologist for PsA, RA; gastroenterologist for UC) or the prescriber has consulted with a specialist in the area of the member's diagnosis
 4. Member does **NOT** have any FDA labeled contraindications to subcutaneous golimumab
 5. Member will **NOT** be using subcutaneous golimumab in combination with another biologic immunomodulator agent (full list in "Other" section); Janus kinase (JAK) inhibitor [Cibinqo (abrocitinib), Leqselvi (deuruxolitinib), Litfulo (ritlectinib), Olumiant (baricitinib), Opzelura (ruxolitinib), Rinvoq/Rinvoq LQ (upadacitinib), and Xeljanz/Xeljanz XR (tofacitinib)]; Otezla/Otezla XR (apremilast); Sotyktu (deucravacitinib); or sphingosine-1-phosphate (S1P) modulator [Velsipity (etrasimod) and Zeposia (ozanimod)]
 6. **ANY** of the following ("a", "b", "c", or "d"):
 - a. The dosage does not exceed:
 - Loading dose:
 - UC:
 - Adults and pediatric members 40 kg (88 lbs) and greater - initial dose of 200 mg at week 0, 100 mg at week 2, then maintenance dose starting on week 6
 - Pediatric members at least 15 kg (33 lbs) to less than 40 kg (88 lbs) - initial dose of 100 mg at week 0, 50 mg at week 2, then maintenance dose starting on week 6
 - Other indications: no loading dose
 - Maintenance dose for all indications [except pediatric members at least 15 kg (33 lbs) to less than 40 kg (88 lbs) with UC] - 100 mg every 4 weeks (28 days)
 - QL: 50 mg/0.5 mL auto-injector - 1 auto-injector (0.5 mL)/28 days
 - QL: 50 mg/0.5 mL syringe - 1 syringe (0.5 mL)/28 days
 - QL: 100 mg/1 mL auto-injector - 1 auto-injector (1 mL)/28 days
 - QL: 100 mg/1 mL syringe - 1 syringe (1 mL)/28 days
 - Maintenance dose for pediatric members at least 15 kg (33 lbs) to less than 40 kg (88 lbs) with UC - 50 mg every 4 weeks (28 days)
 - QL: 50 mg/0.5 mL auto-injector - 1 auto-injector (0.5 mL)/28 days
 - QL: 50 mg/0.5 mL syringe - 1 syringe (0.5 mL)/28 days
 - b. The member has an FDA labeled indication for the requested agent, **AND EITHER** of the following ("i" or "ii"):
 - i. The requested quantity (dose) does **NOT** exceed the maximum FDA labeled dose for the requested indication, **AND** the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength and/or package size that does not exceed the program quantity limit
 - ii. **ALL** of the following ("1", "2", and "3"):
 1. The requested quantity (dose) exceeds the FDA maximum labeled dose for the requested indication
 2. The member has tried and had an inadequate response to at least a 3-month trial of the maximum FDA labeled dose for the requested indication (medical records required)

3. **EITHER** of the following (“a” or “b”):
 - a. The requested quantity (dose) does **NOT** exceed the maximum compendia supported dose for the requested indication, **AND** the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength/and or package size that does not exceed the program quantity limit
 - b. The requested quantity (dose) exceeds the maximum FDA labeled dose **AND** the maximum compendia supported dose for the requested indication, **AND** there is support for therapy with a higher dose or shortened dosing interval for the requested indication (submitted copy of clinical trials, phase III studies, guidelines required)
- c. The member has a compendia supported indication for the requested agent, **AND EITHER** of the following (“i” or “ii”):
 - i. The requested quantity (dose) does **NOT** exceed the maximum compendia supported dose for the requested indication, **AND** the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength/and or package size that does not exceed the program quantity limit
 - ii. The requested quantity (dose) exceeds the maximum compendia supported dose for the requested indication, **AND** there is support for therapy with a higher dose or shortened dosing interval for the requested indication (submitted copy of clinical trials, phase III studies, guidelines required)
- d. The member does **NOT** have an FDA labeled indication **NOR** a compendia supported indication for the requested agent, **AND BOTH** of the following (“i” and “ii”):
 - i. The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength and/or package size that does not exceed the program quantity limit
 - ii. There is support for therapy with a higher dose or shortened dosing interval for the requested indication (submitted copy of clinical trials, phase III studies, guidelines required)

Compendia Allowed: AHFS, DrugDex 1 or 2a level of evidence, or NCCN 1 or 2a recommended use

Approval duration: 12 months [for UC only, loading dose (doses on week 0 and 2) for 1 month, then maintenance dose for 11 additional months (12 months for total duration of approval)]

Table 1

Diagnosis	Criteria
Moderately to severely active rheumatoid arthritis (RA)	<p>BOTH of the following:</p> <ol style="list-style-type: none"> 1. ONE of the following: <ol style="list-style-type: none"> a. The member has tried and had an inadequate response to maximally tolerated methotrexate (e.g., titrated to 25 mg weekly) after at least a 3-month duration of therapy OR b. The member has tried and had an inadequate response to ONE conventional agent (i.e., hydroxychloroquine, leflunomide, sulfasalazine) used in the treatment of RA after at least a 3-month duration of therapy OR c. The member has an intolerance or hypersensitivity to ONE conventional agent (i.e., methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) used in the treatment of RA

	<p>OR</p> <p>d. The member has an FDA labeled contraindication to ALL conventional agents (i.e., methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) used in the treatment of RA</p> <p>OR</p> <p>e. The member's medication history indicates use of another biologic immunomodulator agent that is FDA labeled or supported in DrugDex with 1 or 2a level of evidence or AHFS for the treatment of RA</p> <p>AND</p> <p>2. ANY of the following (submitted medical records/chart notes are required for confirmation):</p> <p>a. The member has tried and had an inadequate response to at least TWO preferred products after at least a 3-month trial per product</p> <p>OR</p> <p>b. The member has tried and had an inadequate response to ONE preferred product after at least a 3-month duration of therapy, AND an intolerance (defined as an intolerance to the drug or its excipients, not to the route of administration) or hypersensitivity to ONE preferred product</p> <p>OR</p> <p>c. The member has an intolerance (defined as an intolerance to the drug or its excipients, not to the route of administration) or hypersensitivity to at least TWO preferred products</p> <p>OR</p> <p>d. The member has an FDA labeled contraindication to ALL preferred products</p> <p>OR</p> <p>e. ALL preferred products are not clinically appropriate for the member, AND the prescriber has provided a complete list of previously tried products for the requested indication:</p> <p>The preferred RA products are:</p> <ul style="list-style-type: none"> • Adalimumab-aaty • Adalimumab-adaz • Enbrel (etanercept) • Hadlima (adalimumab-bwwd) • Humira (adalimumab) • Rinvoq (upadacitinib) • Simlandi (adalimumab-ryvk) • Xeljanz/Xeljanz XR (tofacitinib)
Active psoriatic arthritis (PsA)	<p>BOTH of the following:</p> <p>1. ONE of the following:</p>

a. The member has tried and had an inadequate response to **ONE** conventional agent (i.e., cyclosporine, leflunomide, methotrexate, sulfasalazine) used in the treatment of PsA after at least a 3-month duration of therapy

OR

b. The member has an intolerance or hypersensitivity to **ONE** conventional agent used in the treatment of PsA

OR

c. The member has an FDA labeled contraindication to **ALL** conventional agents used in the treatment of PsA

OR

d. The member has severe active PsA (e.g., erosive disease, elevated markers of inflammation [e.g., ESR, CRP] attributable to PsA, long-term damage that interferes with function [i.e., joint deformities, vision loss], rapidly progressive)

OR

e. The member has concomitant severe psoriasis (PS) (e.g., greater than 10% body surface area involvement, occurring on select locations [i.e., hands, feet, scalp, face, or genitals], intractable pruritus, serious emotional consequences)

OR

f. The member's medication history indicates use of another biologic immunomodulator agent **OR** Otezla/Otezla XR that is FDA labeled or supported in DrugDex with 1 or 2a level of evidence or AHFS for the treatment of PsA

AND

2. **ANY** of the following (submitted medical records/chart notes are required for confirmation):

a. The member has tried and had an inadequate response to at least **TWO** preferred products after at least a 3-month trial per product

OR

b. The member has tried and had an inadequate response to **ONE** preferred product after at least a 3-month duration of therapy, **AND** an intolerance (defined as an intolerance to the drug or its excipients, not to the route of administration) or hypersensitivity to **ONE** preferred product

OR

c. The member has an intolerance (defined as an intolerance to the drug or its excipients, not to the route of administration) or hypersensitivity to **TWO** preferred products

OR

d. The member has an FDA labeled contraindication to **ALL** preferred products

OR

	<p>e. ALL preferred products are not clinically appropriate for the member, AND the prescriber has provided a complete list of previously tried products for the requested indication</p> <p>The preferred PsA products are:</p> <ul style="list-style-type: none"> • Adalimumab-aaty • Adalimumab-adaz • Cosentyx (secukinumab) • Enbrel (etanercept) • Hadlima (adalimumab-bwwd) • Humira (adalimumab) • Otezla/Otezla XR (apremilast) • Rinvoq/Rinvoq LQ (upadacitinib) • Selarsdi (ustekinumab-aekn) • Simlandi (adalimumab-ryvk) • Skyrizi (risankizumab-rzaa) • Stelara (ustekinumab) • Steqeyma (ustekinumab-stba) • Tremfya (guselkumab) • Xeljanz/Xeljanz XR (tofacitinib) • Yesintek (ustekinumab-kfce)
<p>Moderately to severely active ulcerative colitis (UC)</p>	<p>BOTH of the following:</p> <ol style="list-style-type: none"> 1. ONE of the following: <ol style="list-style-type: none"> a. The member has tried and had an inadequate response to ONE conventional agent (i.e., 6-mercaptopurine, azathioprine, balsalazide, corticosteroids, cyclosporine, mesalamine, sulfasalazine) used in the treatment of UC after at least a 3-month duration of therapy OR b. The member has an intolerance or hypersensitivity to ONE conventional agent used in the treatment of UC OR c. The member has an FDA labeled contraindication to ALL of the conventional agents used in the treatment of UC OR d. The member's medication history indicates use of another biologic immunomodulator agent that is FDA labeled or supported in DrugDex with 1 or 2a level of evidence or AHFS for the treatment of UC AND 2. ANY of the following:

	<p>a. The member has tried and had an inadequate response to at least ONE preferred products after at least a 3-month trial</p> <p>OR</p> <p>b. The member has an intolerance (defined as an intolerance to the drug or its excipients, not to the route of administration) or hypersensitivity to at least ONE preferred product</p> <p>OR</p> <p>c. The member has an FDA labeled contraindication to ALL preferred products</p> <p>OR</p> <p>b. ALL preferred products are NOT clinically appropriate for the member, AND the prescriber has provided a complete list of previously tried products for the requested indication</p> <p>The preferred UC products are:</p> <ul style="list-style-type: none"> • Adalimumab-aaty • Adalimumab-adaz • Entyvio (vedolizumab) subcutaneous injection • Hadlima (adalimumab-bwwd) • Humira (adalimumab) • Selarsdi (ustekinumab-aekn) • Simlandi (adalimumab-ryvk) • Skyrizi (risankizumab-rzaa) • Stelara (ustekinumab) • Steqeyma (ustekinumab-stba) • Tremfya (guselkumab) • Xeljanz/Xeljanz XR (tofacitinib) <ul style="list-style-type: none"> • Yesintek (ustekinumab-kfce)
Active ankylosing spondylitis (AS)	<p>BOTH of the following:</p> <p>1. ONE of the following:</p> <p>a. The member has tried and had an inadequate response to TWO different NSAIDs used in the treatment of AS after at least a 4-week TOTAL duration of therapy</p> <p>OR</p> <p>b. The member has tried and had an inadequate response to ONE NSAID used in the treatment of AS after at least a 4-week duration of therapy, AND an intolerance or hypersensitivity to ONE additional NSAID used in the treatment of AS</p> <p>OR</p> <p>c. The member has an intolerance or hypersensitivity to TWO different NSAIDs used in the treatment of AS</p>

OR

- d. The member has an FDA labeled contraindication to **ALL** NSAIDs used in the treatment of AS

OR

- e. The member's medication history indicates use of another biologic immunomodulator agent that is FDA labeled or supported in DrugDex with 1 or 2a level of evidence or AHFS for the treatment of AS

AND

2. **ANY** of the following (submitted medical records/chart notes are required for confirmation):

- a. The member has tried and had an inadequate response to at least **TWO** preferred products after at least a 3-month trial per product

OR

- b. The member has tried and had an inadequate response to **ONE** preferred product after at least a 3-month duration of therapy, **AND** an intolerance (defined as an intolerance to the drug or its excipients, not to the route of administration) or hypersensitivity to **ONE** preferred product

OR

- c. The member has an intolerance (defined as an intolerance to the drug or its excipients, not to the route of administration) or hypersensitivity to **TWO** preferred products

OR

- d. The member has an FDA labeled contraindication to **ALL** preferred products

OR

- e. **ALL** preferred products are not clinically appropriate for the member, **AND** the prescriber has provided a complete list of previously tried products for the requested indication

The preferred AS products are:

- Adalimumab-aaty
- Adalimumab-adaz
- Cosentyx (secukinumab)
- Enbrel (etanercept)
- Hadlima (adalimumab-bwwd)
- Humira (adalimumab)
- Simlandi (adalimumab-ryvk)
- Rinvoq (upadacitinib)
- Xeljanz/Xeljanz XR (tofacitinib)

Other indications	The member has another FDA labeled indication or an indication supported in DrugDex with 1 or 2a level of evidence, AHFS, or NCCN compendium recommended use 1 or 2a.
-------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Continuation of subcutaneous golimumab (Simponi) meets the definition of medical necessity when **ALL** of the following are met (“1” to “6”):

1. An authorization or reauthorization for subcutaneous golimumab has been previously approved by Florida Blue [Note: members not previously approved for the requested agent will require initial evaluation review]
2. Member has had clinical benefit with subcutaneous golimumab therapy
3. The prescriber is a specialist in the area of the member’s diagnosis (e.g., rheumatologist for PsA, RA; gastroenterologist for UC) or the prescriber has consulted with a specialist in the area of the member’s diagnosis
4. Member does **NOT** have any FDA labeled contraindications to subcutaneous golimumab
5. Member will **NOT** be using subcutaneous golimumab in combination with another biologic immunomodulator agent (full list in “Other” section); Janus kinase (JAK) inhibitor [Cibinqo (abrocitinib), Leqselvi (deuruxolitinib), Litfulo (ritlecitinib), Olumiant (baricitinib), Opzelura (ruxolitinib), Rinvoq/Rinvoq LQ (upadacitinib), and Xeljanz/Xeljanz XR (tofacitinib)]; Otezla/Otezla XR (apremilast); Sotyktu (deucravacitinib); or sphingosine-1-phosphate (S1P) modulator [Velsipity (etrasimod) and Zeposia (ozanimod)]
6. **ANY** of the following (“a”, “b”, “c”, or “d”):
 - a. The dosage does not exceed the following:
 - For all indications [**except** pediatric members at least 15 kg (33 lbs) to less than 40 kg (88 lbs) with UC] - 100 mg every 4 weeks
 - QL: 50 mg/0.5 mL auto-injector - 1 auto-injector (0.5 mL)/28 days
 - QL: 50 mg/0.5 mL syringe - 1 syringe (0.5 mL)/28 days
 - QL: 100 mg/1 mL auto-injector - 1 auto-injector (1 mL)/28 days
 - QL: 100 mg/1 mL syringe - 1 syringe (1 mL)/28 days
 - For pediatric members at least 15 kg (33 lbs) to less than 40 kg (88 lbs) with UC - 50 mg every 4 weeks (28 days)
 - QL: 50 mg/0.5 mL auto-injector - 1 auto-injector (0.5 mL)/28 days
 - QL: 50 mg/0.5 mL syringe - 1 syringe (0.5 mL)/28 days
 - b. The member has an FDA labeled indication for the requested agent, **AND EITHER** of the following (“i” or “ii”):
 - i. The requested quantity (dose) does **NOT** exceed the maximum FDA labeled dose for the requested indication, **AND** the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength and/or package size that does not exceed the program quantity limit
 - ii. **ALL** of the following (“1”, “2”, and “3”):
 1. The requested quantity (dose) exceeds the FDA maximum labeled dose for the requested indication
 2. The member has tried and had an inadequate response to at least a 3-month trial of the maximum FDA labeled dose for the requested indication (medical records required)

3. **EITHER** of the following (“a” or “b”):
 - a. The requested quantity (dose) does **NOT** exceed the maximum compendia supported dose for the requested indication, **AND** the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength/and or package size that does not exceed the program quantity limit
 - b. The requested quantity (dose) exceeds the maximum FDA labeled dose **AND** the maximum compendia supported dose for the requested indication, **AND** there is support for therapy with a higher dose or shortened dosing interval for the requested indication (submitted copy of clinical trials, phase III studies, guidelines required)
- c. The member has a compendia supported indication for the requested agent, **AND EITHER** of the following (“i” or “ii”):
 - i. The requested quantity (dose) does **NOT** exceed the maximum compendia supported dose for the requested indication, **AND** the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength/and or package size that does not exceed the program quantity limit
 - ii. The requested quantity (dose) exceeds the maximum compendia supported dose for the requested indication, **AND** there is support for therapy with a higher dose or shortened dosing interval for the requested indication (submitted copy of clinical trials, phase III studies, guidelines required)
- d. The member does **NOT** have an FDA labeled indication **NOR** a compendia supported indication for the requested agent, **AND BOTH** of the following (“i” and “ii”):
 - i. The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength and/or package size that does not exceed the program quantity limit
 - ii. There is support for therapy with a higher dose or shortened dosing interval for the requested indication (submitted copy of clinical trials, phase III studies, guidelines required)

Compendia Allowed: AHFS, DrugDex 1 or 2a level of evidence, or NCCN 1 or 2a recommended use

Approval duration: 12 months

INTRAVENOUS SIMPONI ARIA (MEDICAL BENEFIT)

Initiation of intravenous (IV) golimumab (Simpsoni Aria) meets the definition of medical necessity when **ALL** of the following are met (“1” and “4”):

1. Intravenous golimumab will be used for the treatment of an indication listed in Table 2 and **ALL** of the indication-specific and maximum-allowable dose criteria are met
2. The prescriber is a specialist in the area of the member’s diagnosis (e.g., rheumatologist for JIA, PsA, RA) or the prescriber has consulted with a specialist in the area of the member’s diagnosis
3. Member does **NOT** have any FDA labeled contraindications to golimumab
4. Member will **NOT** be using IV golimumab in combination with another biologic immunomodulator agent (full list in “Other” section); Janus kinase (JAK) inhibitor [Cibinqo (abrocitinib), Leqselvi (deuruxolitinib), Litfulo (ritlecitinib), Olumiant (baricitinib), Opzelura (ruxolitinib), Rinvoq/Rinvoq LQ (upadacitinib), and Xeljanz/Xeljanz XR (tofacitinib)]; Otezla (apremilast); Sotyktu (deucravacitinib); or sphingosine-1-phosphate (S1P) modulator [Velsipity (etrasimod) and Zeposia (ozanimod)]

Approval duration: 12 months

Table 2

Indications and Specific Criteria

Indication	Specific Criteria	Maximum Allowable Dose*
Active ankylosing spondylitis (AS)	<p>ONE of the following:</p> <ol style="list-style-type: none"> 1. The member has tried and had an inadequate response to TWO different NSAIDs used in the treatment of AS after at least a 4-week total TOTAL duration of therapy <p>OR</p> <ol style="list-style-type: none"> 2. The member has tried and had an inadequate response to ONE NSAID used in the treatment of AS after at least a 4-week duration of therapy AND an intolerance or hypersensitivity to ONE additional NSAID used in the treatment of AS <p>OR</p> <ol style="list-style-type: none"> 3. The member has an intolerance or hypersensitivity to TWO different NSAIDs used in the treatment of AS <p>OR</p> <ol style="list-style-type: none"> 4. The member has an FDA labeled contraindication to ALL NSAIDs used in the treatment of AS <p>OR</p> <ol style="list-style-type: none"> 5. The member's medication history indicates use of another biologic immunomodulator agent that is FDA labeled or supported in DrugDex with 1 or 2a level of evidence or AHFS for the treatment of AS 	2 mg/kg at weeks 0 and 4, then every 8 weeks thereafter starting at week 12
Active psoriatic arthritis (PsA)	<p>ONE of the following:</p> <ol style="list-style-type: none"> 1. The member has tried and had an inadequate response to ONE conventional agent (i.e., cyclosporine, leflunomide, methotrexate, sulfasalazine) used in the treatment of PsA after at least a 3-month duration of therapy <p>OR</p> <ol style="list-style-type: none"> 2. The member has an intolerance or hypersensitivity to ONE conventional agent used in the treatment of PsA <p>OR</p> <ol style="list-style-type: none"> 3. The member has an FDA labeled contraindication to ALL conventional agents used in the treatment of PsA 	<p>Adults (18 years and older):</p> <ul style="list-style-type: none"> • 2 mg/kg at weeks 0 and 4, then every 8 weeks thereafter starting at week 12 <p>Pediatric (<18 years of age):</p> <ul style="list-style-type: none"> • 80 mg/m² (based on BSA) at weeks 0 and 4, then every 8 weeks thereafter starting at week 12

	<p>OR</p> <p>4. The member has severe active PsA (e.g., erosive disease, elevated markers of inflammation [e.g., ESR, CRP] attributable to PsA, long-term damage that interferes with function [i.e., joint deformities, vision loss], rapidly progressive)</p> <p>OR</p> <p>5. The member has concomitant severe psoriasis (PS) (e.g., greater than 10% body surface area involvement, occurring on select locations [i.e., hands, feet, scalp, face, or genitals], intractable pruritus, serious emotional consequences)</p> <p>OR</p> <p>6. The member's medication history indicates use of another biologic immunomodulator agent OR Otezla/Otezla XR that is FDA labeled or supported in DrugDex with 1 or 2a level of evidence or AHFS for the treatment of PsA</p>	
<p>Moderately to severely active rheumatoid arthritis</p>	<p>ONE of the following:</p> <p>1. The member has tried and had an inadequate response to maximally tolerated methotrexate (e.g., titrated to 25 mg weekly) after at least a 3-month duration of therapy</p> <p>OR</p> <p>2. The member has tried and had an inadequate response to ONE conventional agent (i.e., hydroxychloroquine, leflunomide, sulfasalazine) used in the treatment of RA after at least a 3-month duration of therapy</p> <p>OR</p> <p>3. The member has an intolerance or hypersensitivity to ONE conventional agent (i.e., methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) used in the treatment of RA</p> <p>OR</p> <p>4. The member has an FDA labeled contraindication to ALL conventional agents (i.e., methotrexate,</p>	<p>2 mg/kg at weeks 0 and 4, then every 8 weeks thereafter starting at week 12</p>

	<p>hydroxychloroquine, leflunomide, sulfasalazine) used in the treatment of RA</p> <p>OR</p> <p>5. The member's medication history indicates use of another biologic immunomodulator agent that is FDA labeled or supported in DrugDex with 1 or 2a level of evidence or AHFS for the treatment of RA</p>	
<p>Moderately to severely active polyarticular juvenile idiopathic arthritis (PJIA)</p>	<p>ONE of the following:</p> <ol style="list-style-type: none"> 1. The member has tried and had an inadequate response to ONE conventional agent (i.e., methotrexate, leflunomide) used in the treatment of PJIA after at least a 3-month duration of therapy <p>OR</p> <ol style="list-style-type: none"> 2. The member has an intolerance or hypersensitivity to ONE conventional agent used in the treatment of PJIA <p>OR</p> <ol style="list-style-type: none"> 3. The member has an FDA labeled contraindication to ALL conventional agents used in the treatment of PJIA <p>OR</p> <ol style="list-style-type: none"> 4. The member's medication history indicates use of another biologic immunomodulator agent that is FDA labeled or supported in DrugDex with 1 or 2a level of evidence or AHFS for the treatment of PJIA 	<p>Pediatric (<18 years of age):</p> <ul style="list-style-type: none"> • 80 mg/m² (based on BSA) at weeks 0 and 4, then every 8 weeks thereafter starting at week 12
<p>Immunotherapy-related inflammatory arthritis</p>	<p>When ALL of the following are met ("1", "2", and "3"):</p> <ol style="list-style-type: none"> 1. Member has been receiving treatment with an immune checkpoint inhibitor (e.g., ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, darvalumab) <p>AND</p> <ol style="list-style-type: none"> 2. Member has moderate or severe inflammatory arthritis <p>AND</p> <ol style="list-style-type: none"> 3. Member has been unable to taper corticosteroids after 1 week 	<p>2 mg/kg X 1 dose. May repeated one additional 2 mg/kg dose if the member does not have adequate improvement in symptoms.</p>
<p>Other indications</p>	<p>The member has another FDA labeled indication or an indication supported in</p>	<p>Maximum dose supported by the FDA labeled indication or</p>

	DrugDex with 1 or 2a level of evidence, AHFS, or NCCN compendium recommended use 1 or 2a	maximum dose supported in DrugDex with 1 or 2a level of evidence, AHFS, or NCCN compendium recommended use 1 or 2a
<p>*The maximum allowable dose can be exceeded if - (1) the dose is supported in DrugDex with 1 or 2a level of evidence, AHFS, or NCCN compendium recommended use 1 or 2a for the requested indication, OR (2) the prescriber has provided information in support of therapy with a higher dose or shortened dosing interval for the requested indication (submitted copy of clinical trials, phase III studies, guidelines required)</p>		

Continuation of intravenous (IV) golimumab (Simponi Aria) **meets the definition of medical necessity** when **ALL** of the following are met ("1" to "6")

1. An authorization or reauthorization for IV golimumab has been previously approved by Florida Blue or another health plan in the past 2 years for the treatment of a condition listed in Table 3 (except for immune checkpoint inhibitor-related inflammatory arthritis – see initiation criteria), **OR** the member previously met **ALL** indication-specific initiation criteria
2. Member has had clinical benefit with IV golimumab therapy
3. The prescriber is a specialist in the area of the member's diagnosis (e.g., rheumatologist for JIA, PsA, RA) or the prescriber has consulted with a specialist in the area of the member's diagnosis
4. Member does **NOT** have any FDA labeled contraindications to IV golimumab
5. Member will **NOT** be using IV golimumab in combination with another biologic immunomodulator agent (full list in "Other" section); Janus kinase (JAK) inhibitor [Cibinco (abrocitinib), Leqselvi (deuruxolitinib), Litfulo (ritlectinib), Olumiant (baricitinib), Opzelura (ruxolitinib), Rinvoq/Rinvoq LQ (upadacitinib), and Xeljanz/Xeljanz XR (tofacitinib)]; Otezla/Otezla XR (apremilast); Sotyktu (deucravacitinib); or sphingosine-1-phosphate (S1P) modulator [Velsipity (etrasimod) and Zeposia (ozanimod)]
6. **EITHER** of the following ("a" or "b"):
 - a. **ONE** of the following ("i" or "ii"):
 - a. Adult (≥ 18 years) RA, PsA, or AS - the member's dosage does not exceed 2 mg/kg every 8 weeks
 - b. Pediatric (<18 years) PsA or PJIA - the member's dosage does not exceed 80 mg/m² (based on BSA) every 8 weeks
 - b. The dose is supported in DrugDex with 1 or 2a level of evidence, AHFS, or NCCN compendium recommended use 1 or 2a for the requested indication, **OR** the prescriber has provided information in support of therapy with a higher dose or shortened dosing interval for the requested indication (submitted copy of clinical trials, phase III studies, guidelines required)

Approval duration: 12 months

DOSAGE/ADMINISTRATION:

THIS INFORMATION IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE USED AS A SOURCE FOR MAKING PRESCRIBING OR OTHER MEDICAL DETERMINATIONS. PROVIDERS SHOULD REFER TO THE MANUFACTURER'S FULL PRESCRIBING INFORMATION FOR DOSAGE GUIDELINES AND OTHER INFORMATION RELATED TO THIS MEDICATION BEFORE MAKING ANY CLINICAL DECISIONS REGARDING ITS USAGE.

FDA-approved:

- Golimumab subcutaneous (Simponi) is indicated for the treatment of: (1) adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate, (2) adult patients with active psoriatic arthritis (PsA) alone or in combination with methotrexate, (3) adult patients with active ankylosing spondylitis (AS), and (4) adults and pediatric patients weighing at least 15 kg with moderate to severe ulcerative colitis (UC). For RA, PsA, and RA the recommended dosage is 50 mg SQ once every month. For patients with RA, golimumab SQ should be given in combination with methotrexate. For patients with PsA or AS, golimumab SQ may be given with or without methotrexate or other non-biologic DMARDs. For patients with RA, PsA, or AS, corticosteroids, non-biologic DMARDs, and/or NSAIDs may be continued during treatment. For UC, the recommended induction dosage regimen for adults and pediatric patients 40 kg and greater is 200 mg SQ at Week 0, followed by 100 mg at Week 2, and then maintenance therapy with 100 mg every 4 weeks. The recommended induction dosage regimen for pediatric patients at least 15 kg to less than 40 kg is 100 mg SQ at Week 0, followed by 50 mg at Week 2, and then maintenance therapy with 50 mg every 4 weeks. For pediatric patients weighing 15 kg or greater, administer the appropriate dose using the prefilled syringe.
- Golimumab intravenous (Simponi Aria) is indicated for the treatment of (1) adults with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate, (2) active psoriatic arthritis (PsA) in patients 2 years of age and older, (3) adults with active ankylosing spondylitis (AS), and (4) active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older. For adult patients with RA, PsA, or AS, the recommended dosage is 2 mg/kg given as an intravenous infusion over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter. For patients with RA, golimumab IV should be given in combination with methotrexate. For pediatric (<18 years of age) PsA and PJIA, the recommended dosage, based on body surface area (BSA), is 80 mg/m² given as an intravenous infusion over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter.

Dose Adjustments: It appears that no dosage adjustments are required for members with hepatic or renal impairment.

Drug Availability: golimumab is available in the following formulations

- For SQ administration:
 - 50 mg/0.5 mL or 100 mg/mL single dose prefilled SmartJect autoinjector
 - 50 mg/0.5 mL or 100 mg/mL single dose prefilled syringe
- For IV administration:
 - 50 mg/4 mL single-use vial

PRECAUTIONS:

Boxed Warning

WARNING: SERIOUS INFECTIONS and MALIGNANCY

SERIOUS INFECTIONS

Patients treated with Simponi /Simponi Aria are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue Simponi /Simponi Aria if a patient develops a serious infection.

Reported infections with TNF blockers, of which Simponi /Simponi Aria is a member, include:

- Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Test patients for latent

tuberculosis before Simponi /Simponi Aria use and during therapy. Initiate treatment for latent tuberculosis prior to Simponi /Simponi Aria use.

- Invasive fungal infections including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

Consider the risks and benefits of treatment with Simponi /Simponi Aria prior to initiating therapy in patients with chronic or recurrent infection.

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Simponi /Simponi Aria, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, of which Simponi Aria a member.

Contraindications

- None

Precautions/Warnings

- **Serious Infections:** golimumab should not be initiated in members during an active infection. If an infection develops, monitor carefully, and discontinue golimumab if infection becomes serious.
- **Invasive fungal infections:** If a member develops a systemic infection while on golimumab therapy, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic
- **Anaphylaxis:** anaphylaxis or serious allergic reactions may occur.
- **Hepatitis B virus reactivation:** members who are HBV carriers should be monitored during and several months after therapy. If reactivation occurs during therapy, discontinue golimumab and initiate anti-viral therapy.
- **Demyelinating disease:** exacerbation of new onset may occur
- **Cytopenia, pancytopenia:** advise members to seek immediate medical attention if symptoms develop and consider discontinuing golimumab.
- **Heart failure:** worsening or new onset heart failure may occur.
- **Lupus-like syndrome:** discontinue golimumab if syndrome develops.
- **Drug Interactions:** avoid concomitant use with abatacept (Orencia®) and anakinra (Kineret®), due to increased risk of serious infection.
- **Live vaccines:** Avoid administration of live vaccines (e.g., varicella and MMR) in members taking golimumab. If possible, it is recommended that prior to initiating golimumab pediatric patients be brought up to date with all immunizations in agreement with current immunization guidelines. Administration of live vaccines to infants exposed to golimumab in utero is not recommended for 6 months following the mother's last golimumab infusion during pregnancy.
- **Pregnancy and Lactation**

- o Golimumab is classified as pregnancy category B. Developmental toxicity studies performed in animals have revealed no evidence of harm to the fetus. Use during pregnancy should occur only if clearly needed.

BILLING/CODING INFORMATION:

The following codes may be used to describe:

HCPCS Coding (Simponi):

J3590	Unclassified biologicals
-------	--------------------------

HCPCS Coding (Simponi Aria):

J1602	Injection, golimumab, 1 mg, for intravenous use
-------	-------------------------------------------------

ICD-10 Diagnosis Codes That Support Medical Necessity (Simponi):

K51.00 – 51.919	Ulcerative colitis
L40.50	Arthropathic psoriasis, unspecified
L40.51	Distal interphalangeal psoriatic arthropathy
L40.52	Psoriatic arthritis mutilans
L40.53	Psoriatic spondylitis
L40.59	Other psoriatic arthropathy
M05.00 – M05.09	Felty's syndrome
M05.10 – M05.19	Rheumatoid lung disease with rheumatoid arthritis
M05.20 – M05.29	Rheumatoid vasculitis with rheumatoid arthritis
M05.30 – M05.39	Rheumatoid heart disease with rheumatoid arthritis
M05.40 – M05.49	Rheumatoid myopathy with rheumatoid arthritis
M05.50 – M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis
M05.60 – M05.69	Rheumatoid arthritis with involvement of other organs and systems
M05.70 – M05.79	Rheumatoid arthritis with rheumatoid factor without organ or systems involvement
M05.80 – M05.89	Other rheumatoid arthritis with rheumatoid factor
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified
M06.00 – M06.09	Rheumatoid arthritis without rheumatoid factor
M06.20 – M06.29	Rheumatoid bursitis
M06.30 – M06.39	Rheumatoid nodule
M06.4	Inflammatory polyarthropathy [for immunotherapy-related inflammatory arthritis ONLY]
M06.80 – M06.89	Other specified rheumatoid arthritis
M06.9	Rheumatoid arthritis, unspecified
M08.09	Unspecified Juvenile rheumatoid arthritis, multiple sites
M08.1	Juvenile ankylosing spondylitis
M08.3	Juvenile Rheumatoid polyarthritis (seronegative)
M08.89	Other juvenile arthritis, multiple sites
M45.0 – M45.9	Ankylosing spondylitis
M46.81 – M46.89	Other specified inflammatory spondylopathies

ICD-10 Diagnosis Codes That Support Medical Necessity: (Simponi Aria)

L40.50	Arthropathic psoriasis, unspecified
L40.51	Distal interphalangeal psoriatic arthropathy
L40.52	Psoriatic arthritis mutilans
L40.53	Psoriatic spondylitis
L40.59	Other psoriatic arthropathy

M05.00 – M05.09	Felty's syndrome
M05.10 – M05.19	Rheumatoid lung disease with rheumatoid arthritis
M05.20 – M05.29	Rheumatoid vasculitis with rheumatoid arthritis
M05.30 – M05.39	Rheumatoid heart disease with rheumatoid arthritis
M05.40 – M05.49	Rheumatoid myopathy with rheumatoid arthritis
M05.50 – M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis
M05.60 – M05.69	Rheumatoid arthritis with involvement of other organs and systems
M05.70 – M05.79	Rheumatoid arthritis with rheumatoid factor without organ or systems involvement
M05.80 – M05.89	Other rheumatoid arthritis with rheumatoid factor
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified
M06.00 – M06.09	Rheumatoid arthritis without rheumatoid factor
M06.20 – M06.29	Rheumatoid bursitis
M06.30 – M06.39	Rheumatoid nodule
M06.80 – M06.89	Other specified rheumatoid arthritis
M06.9	Rheumatoid arthritis, unspecified
M45.0 – M45.9	Ankylosing spondylitis
M46.81 – M46.89	Other specified inflammatory spondylopathies
T45.AX5A	Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter
T45.AX5D	Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter
T45.AX5S	Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela

REIMBURSEMENT INFORMATION:

Refer to section entitled [POSITION STATEMENT](#).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage Products: No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) were found at the time of the last guideline review date. The Site of Care Policy for Select Specialty Medications does not apply to Medicare Advantage members.

Medicare Part D: Florida Blue has delegated to Prime Therapeutics authority to make coverage determinations for the Medicare Part D services referenced in this guideline.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#).

DEFINITIONS:

DMARDs: an acronym for disease-modifying antirheumatic drugs. These are drugs that modify the rheumatic disease processes, and slow or inhibit structural damage to cartilage and bone. These drugs are unlike symptomatic treatments such as NSAIDs that do not alter disease progression. DMARDs can be further subcategorized. With the release of biologic agents (e.g., anti-TNF drugs), DMARDs were divided into either: (1) conventional, traditional, synthetic, or non-biologic DMARDs; or as (2) biological DMARDs. However, with the release of newer targeted non-biologic drugs and biosimilars, DMARDs are

now best categorized as: (1) conventional synthetic DMARDs (csDMARD) (e.g., MTX, sulfasalazine), (2) targeted synthetic DMARDs (tsDMARD) (e.g., baricitinib, tofacitinib, apremilast), and (3) biological DMARDs (bDMARD), which can be either a biosimilar DMARD (bsDMARD) or biological originator DMARD (boDMARD).

Psoriatic Arthritis (PsA): joint inflammation that occurs in about 5% to 10% of people with psoriasis (a common skin disorder). It is a severe form of arthritis accompanied by inflammation, psoriasis of the skin or nails, and a negative test for rheumatoid factor. Enthesitis refers to inflammation of entheses, the site where ligaments or tendons insert into the bones. It is a distinctive feature of PsA and does not occur with other forms of arthritis. Common locations for enthesitis include the bottoms of the feet, the Achilles' tendons, and the places where ligaments attach to the ribs, spine, and pelvis.

Rheumatoid Arthritis: An inflammatory disease of the synovium or lining of the joint that results in pain stiffness and swelling of multiple joints. The inflammation may extend to other joints and cause bone and cartilage erosion, joint deformities, movement problems, and activity limitations.

Ulcerative Colitis: a form of inflammatory bowel disease that includes characteristic ulcers or open sores. The main symptoms of active disease are usually consistent with diarrhea mixed with blood, of gradual onset. It is an intermittent disease, with periods of exacerbated symptoms, and periods that are relatively symptom-free.

RELATED GUIDELINES:

[Abatacept \(Orencia\), 09-J0000-67](#)

[Adalimumab Products, 09-J0000-46](#)

[Anakinra \(Kineret\), 09-J0000-45](#)

[Apremilast \(Otezla Tablet, 09-J2000-19](#)

[Baricitinib \(Olumiant\), 09-J3000-10](#)

[Certolizumab Pegol \(Cimzia\), 09-J0000-77](#)

[Etanercept \(Enbrel\), 09-J0000-38](#)

[Etrasimod \(Velsipity\), 09-J4000-72](#)

[Infliximab Products, 09-J0000-39](#)

[Mirikizumab \(Omvoh\), 09-J4000-71](#)

[Natalizumab \(Tysabri\) Injection, 09-J0000-73](#)

[Rituximab Products, 09-J0000-59](#)

[Sarilumab \(Kevzara\), 09-J2000-87](#)

[Secukinumab \(Cosentyx\), 09-J2000-30](#)

[Tocilizumab Products \(Actemra, Tofidence, Tyenne\), 09-J1000-21](#)

[Tofacitinib \(Xeljanz, Xeljanz XR\) Oral Solution, Tablet and Extended-Release Tablet, 09-J1000-86](#)

[Upadacitinib \(Rinvoq\), 09-J3000-51](#)

[Ustekinumab \(Stelara\), 09-J1000-16](#)

[Vedolizumab \(Entyvio\), 09-J2000-18](#)

OTHER:

NOTE: The list of biologic immunomodulator agents not permitted as concomitant therapy can be found at [Biologic Immunomodulator Agents Not Permitted as Concomitant Therapy](#).

Table 3: Conventional Synthetic DMARDs

Generic Name	Brand Name
Auranofin (oral gold)	Ridaura
Azathioprine	Imuran
Cyclosporine	Neoral, Sandimmune
Hydroxychloroquine	Plaquenil
Leflunomide	Arava
Methotrexate	Rheumatrex, Trexall

Sulfasalazine	Azulfidine, Azulfidine EN-Tabs
---------------	--------------------------------

Table 4: Grading of Severity of Rheumatoid Arthritis

Severity	Criteria
Mild	Joint pain Inflammation of at least 3 joints No inflammation in tissues other than the joints Usually, a negative result on a rheumatoid factor test An elevated erythrocyte sedimentation rate (ESR) or C reactive protein (CRP) level No evidence of bone or cartilage damage on x-rays
Moderate	Between 6 and 20 inflamed joints Usually no inflammation in tissues other than the joints An elevated ESR or CRP levels A positive rheumatoid factor test or anti-cyclic citrullinated peptide (anti-CCP) antibodies Evidence of inflammation but no evidence of bone damage on x-rays
Severe	More than 20 persistently inflamed joints or a rapid loss of functional abilities Elevated ESR or CRP levels Anemia related to chronic illness Low blood albumin level A positive rheumatoid factor test, often with a high level Evidence of bone and cartilage damage on x-ray Inflammation in tissues other than joints

REFERENCES:

1. Bansback N, Phibbs CS, Sun H1, et al; CSP 551 RACAT Investigators. Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. *Ann Intern Med.* 2017 Jul 4;167(1):8-16.
2. Bautista-Molano W, Fernández-Ávila DG, et al. Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis. *Nat Rev Rheumatol.* 2023 Nov;19(11):724-737. doi: 10.1038/s41584-023-01034-z. Epub 2023 Oct 6.
3. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res* 2011;63(4): 465-82.
4. Callhoff J, Sieper J, Weiß A, et al. Efficacy of TNF α blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. *Ann Rheum Dis.* 2015 Jun;74(6):1241-8.
5. Clinical Pharmacology powered by ClinicalKey [Internet]. Tampa, FL: Elsevier.; 2025. Available at: <https://www.clinicalkey.com/pharmacology/>. Accessed 10/29/25.
6. Coates LC, Soriano ER, Corp N, et al; GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. *Nat Rev Rheumatol.* 2022 Aug;18(8):465-479. Epub 2022 Jun 27. Erratum in: *Nat Rev Rheumatol.* 2022 Dec;18(12):734.
7. FDA Orphan Drug Designations and Approvals [Internet]. Washington, D.C. [cited 2025 Oct 29]. Available from: <http://www.accessdata.fda.gov/scripts/opdlisting/oopd/>.
8. Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, Terdiman JP; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology.* 2021 Jun;160(7):2496-2508.

9. Feuerstein JD, Isaacs KL, Schneider Y, et al.; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. *Gastroenterology*. 2020 Apr;158(5):1450-1461. 2020 Jan 13.
10. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2021 Jul;73(7):924-939.
11. Graudal N, Hubeck-Graudal T, Tarp S, et al. Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials. *PLoS One*. 2014 Sep 22;9(9):e106408.
12. Ko CW, Singh S, Feuerstein JD, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. *Gastroenterology*. 2019 Feb;156(3):748-764.
13. Krause ML, Amin A, and Makol A. Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. *Ther Adv Musculoskelet Dis*. 2014 Oct; 6(5): 169–184.
14. Kroon FP, van der Burg LR, Ramiro S, et al. non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). *Cochrane Database Syst Rev*. 2015 Jul 17;7:CD010952.
15. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. *J Am Acad Dermatol* 2011; 65:137-74.
16. Micromedex Healthcare Series [Internet Database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed 10/29/25.
17. National Comprehensive Cancer Network. Cancer Guidelines. Cancer Guidelines and Drugs and Biologics Compendium. Accessed 10/29/25.
18. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Management of Immune Checkpoint Inhibitor-Related Toxicities. Version 1.2026 - October 23, 2025. Available at https://www.nccn.org/professionals/physician_gls/pdf/ici_tox.pdf. Accessed 10/29/25.
19. Peper SM, Lew R, Mikuls T, et al. Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept. *Arthritis Care Res (Hoboken)*. 2017 Oct;69(10):1467-1472.
20. Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. *Reprod. Toxicol*; 2008;25,271–275.
21. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. *Ann Rheum Dis*. 2022 Oct 19: ard-2022-223297. Epub ahead of print.
22. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. *Arthritis Rheumatol*. 2019 Jun;71(6):846-863. Epub 2019 Apr 25
23. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. *Am J Gastroenterol*. 2025 Jun 3;120(6):1187-1224.
24. Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis*. 2011 Jan;70(1):25-31.
25. Scott DL, Ibrahim F, Farewell V, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. *BMJ*. 2015 Mar 13;350:h1046.

26. Scott DL, Kinglsey GH. Tumor necrosis factor inhibitors in rheumatoid arthritis. N Engl J Med 2006; 355:704-12.
27. Simponi (golimumab) [package insert]. Janssen Biotech Inc. Horsham (PA):October 2025.
28. Simponi Aria (golimumab) [package insert]. Janssen Biotech Inc. Horsham (PA): April 2025.
29. Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5-32. Epub 2018 Nov 30.
30. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. Epub 2022 Nov 10. Erratum in: Ann Rheum Dis. 2023 Mar;82(3):e76.
31. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Ther 2008; 117:244-79.
32. van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2-year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012 May 5;379(9827):1712-20.
33. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 Oct;71(10):1285-1299. Epub 2019 Aug 21.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Pharmacy Policy Committee on 11/12/25.

GUIDELINE UPDATE INFORMATION:

08/15/09	New Medical Coverage Guideline.
04/15/10	Revision; consisting of adding specific continuation criteria.
09/15/10	Review and revision; consisting of Updating boxed warning, precautions section and references.
01/15/11	Revision; consisting of adding ICD-10 codes.
04/01/11	Revision; consisting of adding dosage limits.
09/15/11	Review and revision to guideline; consisting of updating coding and references.
04/15/12	Revision to guideline consisting of removing failure of DMARD for ankylosing spondylitis.
09/15/12	Review and revision to guideline; consisting of modifying continuation criteria, reformatting position statement, updating precautions, program exceptions and references.
01/15/13	Revision to guideline; consisting of reformatting/revising the position statement, dosage/administration, precautions sections; updating references and decision tree.
4/15/13	Revision of guideline; consisting of revising position statement to include duration of approval and Orphan Drug indications.
09/15/13	Review and revision to guideline; consisting of revising position statement to include coverage of ulcerative colitis, revising dosage/administration section, updating references, related guidelines, definitions, program exceptions, and coding.
11/15/13	Revision to guideline; consisting of adding new product to guideline, updating position statement, coding, and references.
01/01/14	Revision to guideline, consisting of coding update.
04/15/14	Revision to guideline; consisting of adding clarification statement and reformatting position statement.

09/15/14	Review and revision to guideline; consisting of updating position statement, references, coding, and related guidelines.
09/15/15	Review and revision to guideline; consisting of updating description section, position statement, dosage/administration, warnings/precautions, billing/coding, related guidelines, and references.
11/01/15	Revision: ICD-9 Codes deleted.
09/15/16	Review and revision to guideline consisting of updating description section, position statement, billing/coding, and references.
10/15/17	Review and revision to guideline consisting of updating description, position statement, definitions, related guidelines, and references.
01/01/18	Revision to guideline consisting of updating the description section, position statement, and references after golimumab IV (Simponi Aria) gained new FDA-approved indications for psoriatic arthritis and ankylosing spondylitis. The preferred self-administered biologic products were also updated according to indication for use.
07/01/18	Revision to guideline consisting of updating the position statement.
10/15/18	Review and revision to guideline consisting of updating the position statement, related guidelines and references.
10/15/19	Review and revision to guideline consisting of updating the position statement, billing/coding, and references.
11/11/19	Revision to guideline consisting of adding a reference to the Site of Care Policy for Select Specialty Medications and updating the Program Exceptions.
01/01/20	Revision to guideline consisting of updating the position statement due to changes in preferred and non-preferred products.
07/01/20	Revision to guideline consisting of updating the description, position statement, and definitions.
01/01/21	Review and revision to guideline consisting of updating the description, position statement, dosage/administration, precautions, billing/coding, and references.
03/15/21	Revision to guideline consisting of updating the position statement.
09/15/21	Update to Table 1 in Position Statement.
11/15/21	Revision to guideline consisting of updating the position statement.
01/01/22	Review and revision to guideline consisting of updating the description, position statement, related guidelines, other section, and references.
02/15/22	Update to Table 1 in Position Statement.
03/15/22	Revision to guideline consisting of updating the position statement and other section.
05/15/22	Update to Table 1 in Position Statement.
07/15/22	Revision to guideline consisting of updating the position statement.
09/15/22	Update to Table 1 in Position Statement.
01/01/23	Review and revision to guideline consisting of updating the position statement, other section, and references. New drugs were added to the list of drugs that are not permitted for use in combination.
04/15/23	Revision to guideline consisting of updating the position statement and other section.
07/01/23	Revision to guideline consisting of updating the position statement and other section. Amjevita and Hadlima added as Step 1a agents. Humira biosimilar products added to list of Biologic Immunomodulator Agents Not Permitted as Concomitant Therapy.
01/01/24	Review and revision to guideline consisting of updating the description (NCCN info), position statement, other section, billing/coding, and references. Amjevita low-concentration [10 mg/0.2 mL, 20 mg/0.4 mL, and 40 mg/0.8 mL concentrations only] clarified as the preferred prerequisite product. Immunotherapy-related inflammatory arthritis added as a new indication for Simponi Aria. Update to Table 1 in Position Statement. New drugs were added to the list of drugs that are not permitted for use in combination.
07/01/24	Revision to guideline consisting of updating the position statement, related guidelines, and other section. Amjevita low-concentration removed as a required prerequisite agent. Updates to the positioning of agents in Table 1. Removal of latent TB testing requirement.

	New drugs added to the list of Biologic Immunomodulator Agents Not Permitted as Concomitant Therapy.
10/01/24	Revision to guideline consisting of updating the position statement and billing/coding. Updates to Table 1. Simlandi added among the required prerequisite agents for Simponi for AS, RA, UC, and PsA. Rinvoq LQ added among the required prerequisite agents for Simponi for PsA. Skyrizi added among the required prerequisite agents for Simponi for UC. New ICD-10 codes related to adverse effect of immune checkpoint inhibitors.
01/01/25	Review and revision to guideline consisting of updating the position statement, other section, and references. Adalimumab-aaty and Adalimumab-adaz added among the prerequisite therapies for AS, PsA, RA, and UC for Simponi. Entyvio SC and Tremfya added among the prerequisite therapies for UC for Simponi (when other drugs are contraindication or not clinically appropriate). Update to original Table 1 which is now a link out from the Position Statement. Table titles updated. Revised wording regarding maximum dosage exceptions for Simponi. New drugs were added to the list of drugs that are not permitted for use in combination.
07/01/25	Revision: Added Selarsdi, Steqeyma and Yesintek among the preferred agents for PsA for Simponi.
01/01/26	Review and revision to guideline consisting of updating the description, position statement, dosage/administration, precautions, and references. The indication for moderately to severely active UC was expanded to include pediatric patients weighing at least 15 kg. A lower dosage is required for patients between 15 kg and 40 kg.
06/01/26	Revision: Added Drug Waste Reduction statement to the Position Statement.